Analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will announce earnings of ($0.74) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is ($0.77) and the highest is ($0.71). Crispr Therapeutics reported earnings per share of ($0.40) during the same quarter last year, which indicates a negative year over year growth rate of 85%. The company is expected to report its next quarterly earnings results on Friday, March 9th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.49) to ($2.43). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.06) per share, with EPS estimates ranging from ($3.08) to ($3.04). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million for the quarter, compared to analyst estimates of $3.61 million. During the same quarter in the previous year, the business posted ($2.77) earnings per share. The company’s revenue was up 54.2% compared to the same quarter last year.
Several brokerages have recently issued reports on CRSP. Oppenheimer began coverage on Crispr Therapeutics in a report on Thursday, December 7th. They set a “hold” rating for the company. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 4th. Piper Jaffray Companies reiterated a “buy” rating and set a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a report on Wednesday. SunTrust Banks reiterated a “hold” rating and set a $16.00 price target on shares of Crispr Therapeutics in a report on Friday, November 10th. Finally, Cann reiterated a “hold” rating on shares of Crispr Therapeutics in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Crispr Therapeutics presently has a consensus rating of “Buy” and an average price target of $22.81.
Shares of Crispr Therapeutics (NASDAQ:CRSP) opened at $28.52 on Friday. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $30.79. The company has a market capitalization of $1,170.00 and a PE ratio of -89.13.
In related news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $18.98, for a total value of $21,114,225.08. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kurt Von Emster sold 37,754 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $26.76, for a total value of $1,010,297.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,168,504 shares of company stock valued at $42,538,573. 39.98% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of CRSP. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Vanguard Group Inc. bought a new position in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $273,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $206,000. Moloney Securities Asset Management LLC bought a new position in Crispr Therapeutics in the 3rd quarter worth approximately $235,000. Finally, Hershey Trust Co. bought a new position in Crispr Therapeutics in the 3rd quarter worth approximately $768,000. 24.52% of the stock is currently owned by institutional investors and hedge funds.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.